Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test.
Shun IshidoNobuharu TamakiKento InadaJun ItakuraYuka TakahashiNaoki UchiharaKeito SuzukiYuki TanakaHaruka MiyamotoMichiko YamadaHiroaki MatsumotoTsubasa NobusawaTaisei KeitokuKenta TakauraShohei TanakaChiaki MaeyashikiYutaka YasuiKaoru TsuchiyaHiroyuki NakanishiMasayuki KurosakiNamiki IzumiPublished in: Clinical case reports (2023)
The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.